Another Precious Child Falls Victim to the California Vaccine Mandates
MMRV Vaccine made my child disabled in 3 days.
I am a desperate parent looking for local and social media to help me to investigate my 6 year old child losing her ability to coordinate eyes just 3 days after MMRV vaccine.
In the last week, my daughter was misdiagnosed, let go untreated from hospital totaling in 4 visits and just got released with “maybe” hopes to regain her normal vision. I am puzzled and torn apart how on 4/14/16 child that has been examined by her pediatrician and found perfectly healthy end up being disabled after MMRV vaccine in 3 days.
Please help me bring awareness of this incident and locate medical professional to help my daughter to regain her vision back. Thank you!”
Recurrent 6th nerve palsy in a child following different live attenuated vaccines: case report
Recurrent benign 6th nerve palsy in the paediatric age group is uncommon, but has been described following viral and bacterial infections. It has also been temporally associated with immunization, but has not been previously described following two different live attenuated vaccines.
The majority of benign 6th nerve palsies do not have a sinister cause and have an excellent prognosis, with recovery expected in most cases. The exact pathophysiology is unknown, although hypotheses including autoimmune mechanisms and direct viral invasion could explain the pathophysiology behind immunization related nerve palsies. It is important to rule out other aetiologies with thorough history, physical examination and investigations. There is limited information in the literature regarding the safety of a repeat dose of a live vaccine in this setting. Future immunizations should be considered on a case-by-case basis.
Hepatitis B Vaccine for Infants: Is it Worth It?
Here are some studies that have investigated the health effects of hepatitis B vaccine in U.S. children:
Controlling for age, race and gender simultaneously in the 1994 NHIS, hepatitis B vaccine was found to be associated with prevalent arthritis [odds ratio (OR) = 5.91], incident acute ear infections (OR = 1.60), and incident pharyngitis/nasopharyngitis (OR = 1.41).
Hepatitis B vaccinated children had an unadjusted odds ratio of 2.94 and age-adjusted odds ratio of 2.35 for liver problems compared with non-hepatitis B vaccinated children in the 1993 National Health Interview Survey. Hepatitis B vaccinated children had an unadjusted odds ratio of 2.57 and age-adjusted odds ratio of 1.53 for liver problems compared with non-hepatitis B vaccinated children in the 1994 National Health Interview Survey Dataset.
In people not previously exposed to hepatitis B, vaccination has unclear effect on the risk of developing infection, as compared to no vaccination. The risk of lacking protective antibody levels as well as serious and non-serious adverse events appear comparable among recipients and non-recipients of hepatitis B vaccine. (no benefit from receiving the vaccine)
This study investigated the association between vaccination with the Hepatitis B triple series vaccine prior to 2000 and developmental disability in children aged 1-9 years (n=1824), proxied by parental report that their child receives early intervention or special education services (EIS)… The odds of receiving EIS were approximately nine times as great for vaccinated boys as for unvaccinated boys…This study found statistically significant evidence to suggest that boys in the United States who were vaccinated with the triple series Hepatitis B vaccine, during the time period in which vaccines were manufactured with thimerosal, were more susceptible to developmental disability than were unvaccinated boys.
Boys vaccinated as neonates had threefold greater odds for autism diagnosis compared to boys never vaccinated or vaccinated after the first month of life. Findings suggest that U.S. male neonates vaccinated with the hepatitis B vaccine prior to 1999 (from vaccination record) had a threefold higher risk for parental report of autism diagnosis compared to boys not vaccinated as neonates during that same time period.
The last two articles listed above involved data analysis for children who received the hepatitis B vaccine prior to the elimination of thimerosal, or mercury from the vaccine. This may lead you to believe once that was accomplished the problem was solved. The current hepatitis B vaccines contain high amounts of aluminum. The following articles have to do with the problems associated with aluminum in infant vaccines:
In the present review we describe how the use of a systems biology approach in cultured hepatoblastoma cells (HepG2) allowed the identification of the molecular targets of Al toxicity. Mitochondrial metabolism is the main site of the toxicological action of Al. Fe-dependent and redox sensitive enzymes in the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) are dramatically decreased by Al exposure. In an effort to compensate for diminished mitochondrial function, Al-treated cells stabilize hypoxia inducible factor -1a (HIF-1a) to increase ATP production by glocolysis. Additionally, Al toxicity leads to an increase in intracellular lipid accumulation due to enhanced lipogenesis and a decrease in the B-oxidation of fatty acids. Central to these effects is the alteration of a-ketoglutarate (KG) homeostasis. In Al-exposed cells, KG is preferentially used to quench ROS leading to succinate accumulation and HIF-1a stabilization. Moreover, the channeling of KG to combat oxidative stress leads to a reduction of L-carnitine biosynthesis and a concomitant decrease in fatty acid oxidation. The fluidity and interaction of these metabolic modules and the implications of these findings in liver-related disorders are discussed herein.
(Note: The importance of these findings is relevant especially for brain development and for chronic autoimmune disorders such as diabetes and autism. The disruption of mitochondrial metabolism is significant in the increased risk of vaccine-injury in persons who have underlying mitochondrial disorders.)
When assessing adjuvant toxicity in children, several key points ought to be considered:
(i) infants and children should not be viewed as “small adults” with regard to toxicological risk as their unique physiology makes them much more vulnerable to toxic insults;
(ii) in adult humans Al vaccine adjuvants have been linked to a variety of serious autoimmune and inflammatory conditions (i.e., “ASIA”), yet children are regularly exposed to much higher amounts of Al from vaccines than adults;
(iii) it is often assumed that peripheral immune responses do not affect brain function. However, it is now clearly established that there is a bidirectional neuro-immune cross-talk that plays crucial roles in immunoregulation as well as brain function. In turn, perturbations of the neuro-immune axis have been demonstrated in many autoimmune diseases encompassed in “ASIA” and are thought to be driven by a hyperactive immune response;
(iv) the same components of the neuro-immune axis that play key roles in brain development and immune function are heavily targeted by Al adjuvants. In summary, research evidence shows that increasing concerns about current vaccination practices may indeed be warranted. Because children may be most at risk of vaccine-induced complications, a rigorous evaluation of the vaccine-related adverse health impacts in the pediatric population is urgently needed.
With all of these concerns about the safety of aluminum in vaccines, and about the Hepatitis B vaccine in particular, you may be led to ask yourself, “Is it worth it?”